Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04208698 · ClinicalTrials.gov registry record · Phase 2
A Scintigraphy Study in Adults With Diabetic Gastroparesis
A Phase 2 study, sponsored by CinDome Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04208698: Clinical Trial Phase 2 study, sponsored by CinDome Pharma.
NCT04208698 is a Phase 2 study that was terminated before completion, run by CinDome Pharma. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04208698, a Phase 2 study, was terminated before completion, sponsored by CinDome Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
Interventions
- DRUG CIN-102 Dose 1
- DRUG CIN-102 Dose 2
- DRUG Placebo for CIN-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Why NCT04208698 stopped before completion
NCT04208698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which CIN-102 Dose 1 is the first listed.
NCT04208698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04208698 about?
NCT04208698 is a clinical study titled "A Scintigraphy Study in Adults With Diabetic Gastroparesis". This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
What is the current status of trial NCT04208698?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-02-17. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04208698?
The interventions under investigation include: CIN-102 Dose 1 (DRUG), CIN-102 Dose 2 (DRUG), Placebo for CIN-102 (DRUG).
Who is sponsoring clinical trial NCT04208698?
This trial is sponsored by CinDome Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04208698's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI